CO2020015685A2 - Composición que comprende el oligonucleótido antisentido y su uso para el tratamiento de la distrofia muscular de duchenne - Google Patents
Composición que comprende el oligonucleótido antisentido y su uso para el tratamiento de la distrofia muscular de duchenneInfo
- Publication number
- CO2020015685A2 CO2020015685A2 CONC2020/0015685A CO2020015685A CO2020015685A2 CO 2020015685 A2 CO2020015685 A2 CO 2020015685A2 CO 2020015685 A CO2020015685 A CO 2020015685A CO 2020015685 A2 CO2020015685 A2 CO 2020015685A2
- Authority
- CO
- Colombia
- Prior art keywords
- treatment
- muscular dystrophy
- duchenne muscular
- composition
- antisense oligonucleotide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/33—Alteration of splicing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a una composición que contiene un oligonucleótido antisentido y al uso del mismo para tratar la distrofia muscular de Duchenne. La presente invención se refiere en particular a la composición descrita anteriormente que es eficaz para el tratamiento de la distrofia muscular de Duchenne cuando se administra en una dosis para el tratamiento y el uso de la misma.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862690270P | 2018-06-26 | 2018-06-26 | |
US201862739386P | 2018-10-01 | 2018-10-01 | |
PCT/JP2019/026393 WO2020004675A1 (ja) | 2018-06-26 | 2019-06-26 | アンチセンスオリゴヌクレオチドを含有する組成物およびデュシェンヌ型筋ジストロフィーの治療へのその使用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2020015685A2 true CO2020015685A2 (es) | 2021-04-30 |
Family
ID=68987235
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2020/0015685A CO2020015685A2 (es) | 2018-06-26 | 2020-12-14 | Composición que comprende el oligonucleótido antisentido y su uso para el tratamiento de la distrofia muscular de duchenne |
Country Status (19)
Country | Link |
---|---|
US (2) | US20210261963A1 (es) |
EP (1) | EP3815696A4 (es) |
JP (2) | JP7345466B2 (es) |
KR (1) | KR20210023988A (es) |
CN (1) | CN112399849A (es) |
AU (1) | AU2019293687A1 (es) |
BR (1) | BR112020026542A2 (es) |
CA (1) | CA3101321A1 (es) |
CL (1) | CL2020003367A1 (es) |
CO (1) | CO2020015685A2 (es) |
EC (1) | ECSP20083454A (es) |
IL (1) | IL279692A (es) |
MX (1) | MX2020013880A (es) |
PE (1) | PE20210630A1 (es) |
PH (1) | PH12020552078A1 (es) |
SG (1) | SG11202011554PA (es) |
TW (1) | TW202035692A (es) |
WO (1) | WO2020004675A1 (es) |
ZA (1) | ZA202007682B (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3216839A1 (en) | 2021-04-30 | 2022-11-03 | Sarepta Therapeutics, Inc. | Treatment methods for muscular dystrophy |
WO2023178230A1 (en) | 2022-03-17 | 2023-09-21 | Sarepta Therapeutics, Inc. | Phosphorodiamidate morpholino oligomer conjugates |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR0167574B1 (ko) | 1989-12-20 | 1999-01-15 | 제임스 섬머톤 | 소단위 사이에 인-함유 키랄결합을 가지는 비전하 모르폴리노기저 중합체 |
ES2561851T3 (es) | 2002-11-25 | 2016-03-01 | Masafumi Matsuo | Fármacos de ácido nucleico ENA que modifican el corte y empalme en precursores de ARNm |
ES2361325T3 (es) | 2004-06-28 | 2011-06-16 | The University Of Western Australia | Oligonucleótidos antisentido para inducir la omisión de exón y métodos de uso de los mismos. |
EP1811024A1 (en) | 2004-10-05 | 2007-07-25 | Nippon Shinyaku Co., Ltd. | Oligo double-stranded rna and medicinal composition |
JP5056413B2 (ja) | 2005-05-30 | 2012-10-24 | 日本新薬株式会社 | 核酸含有複合体製剤の製造方法 |
BR122019021332A8 (pt) | 2007-11-15 | 2022-12-06 | Avi Biopharma Inc | Processo de síntese de oligômeros de morfolino |
US8084601B2 (en) | 2008-09-11 | 2011-12-27 | Royal Holloway And Bedford New College Royal Holloway, University Of London | Oligomers |
PL3133160T3 (pl) | 2008-10-24 | 2019-06-28 | Sarepta Therapeutics, Inc. | Kompozycje do pomijania eksonów w DMD |
TWI541024B (zh) * | 2010-09-01 | 2016-07-11 | 日本新藥股份有限公司 | 反義核酸 |
JP2015509922A (ja) * | 2012-01-27 | 2015-04-02 | プロセンサ テクノロジーズ ビー.ブイ.Prosensa Technologies B.V. | デュシェンヌ型及びベッカー型筋ジストロフィーの治療のための改善された特徴を有するrna調節オリゴヌクレオチド |
PL2970964T3 (pl) * | 2013-03-14 | 2019-06-28 | Sarepta Therapeutics, Inc. | Kompozycje pomijające eksony do leczenia dystrofii mięśniowej |
KR20200139271A (ko) | 2013-03-15 | 2020-12-11 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | 근육 이영양증의 치료를 위한 개선된 조성물 |
JP6477464B2 (ja) * | 2013-05-24 | 2019-03-06 | 味の素株式会社 | モルフォリノオリゴヌクレオチドの製造方法 |
EP3355892A4 (en) * | 2015-09-30 | 2019-05-22 | Sarepta Therapeutics, Inc. | METHODS OF TREATING MUSCLE DYSTROPHY |
FR3044926B1 (fr) * | 2015-12-09 | 2020-01-31 | Genethon | Outils de therapie genique efficaces pour le saut de l'exon 53 de la dystrophine |
-
2019
- 2019-06-26 CN CN201980043482.XA patent/CN112399849A/zh active Pending
- 2019-06-26 BR BR112020026542-0A patent/BR112020026542A2/pt unknown
- 2019-06-26 JP JP2020527712A patent/JP7345466B2/ja active Active
- 2019-06-26 CA CA3101321A patent/CA3101321A1/en active Pending
- 2019-06-26 EP EP19826094.5A patent/EP3815696A4/en active Pending
- 2019-06-26 SG SG11202011554PA patent/SG11202011554PA/en unknown
- 2019-06-26 PE PE2020002157A patent/PE20210630A1/es unknown
- 2019-06-26 KR KR1020217001037A patent/KR20210023988A/ko unknown
- 2019-06-26 AU AU2019293687A patent/AU2019293687A1/en active Pending
- 2019-06-26 US US17/253,760 patent/US20210261963A1/en not_active Abandoned
- 2019-06-26 TW TW108122381A patent/TW202035692A/zh unknown
- 2019-06-26 MX MX2020013880A patent/MX2020013880A/es unknown
- 2019-06-26 WO PCT/JP2019/026393 patent/WO2020004675A1/ja active Application Filing
-
2020
- 2020-12-02 PH PH12020552078A patent/PH12020552078A1/en unknown
- 2020-12-09 ZA ZA2020/07682A patent/ZA202007682B/en unknown
- 2020-12-14 CO CONC2020/0015685A patent/CO2020015685A2/es unknown
- 2020-12-22 IL IL279692A patent/IL279692A/en unknown
- 2020-12-23 EC ECSENADI202083454A patent/ECSP20083454A/es unknown
- 2020-12-23 CL CL2020003367A patent/CL2020003367A1/es unknown
-
2023
- 2023-09-05 JP JP2023143451A patent/JP2023171731A/ja active Pending
- 2023-11-08 US US18/504,781 patent/US20240158792A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
ECSP20083454A (es) | 2021-01-29 |
AU2019293687A1 (en) | 2021-01-07 |
US20240158792A1 (en) | 2024-05-16 |
EP3815696A4 (en) | 2022-11-30 |
CL2020003367A1 (es) | 2021-05-24 |
WO2020004675A1 (ja) | 2020-01-02 |
BR112020026542A2 (pt) | 2021-04-06 |
EP3815696A1 (en) | 2021-05-05 |
CA3101321A1 (en) | 2020-01-02 |
CN112399849A (zh) | 2021-02-23 |
PH12020552078A1 (en) | 2021-05-31 |
TW202035692A (zh) | 2020-10-01 |
JPWO2020004675A1 (ja) | 2021-07-15 |
PE20210630A1 (es) | 2021-03-23 |
MX2020013880A (es) | 2021-03-09 |
JP7345466B2 (ja) | 2023-09-15 |
ZA202007682B (en) | 2024-04-24 |
JP2023171731A (ja) | 2023-12-05 |
SG11202011554PA (en) | 2020-12-30 |
KR20210023988A (ko) | 2021-03-04 |
US20210261963A1 (en) | 2021-08-26 |
IL279692A (en) | 2021-03-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2019000107A1 (es) | Composiciones de arni contra el componente c5 del complemento y métodos para su uso.(divisional solicitud 201702014) | |
CL2017002636A1 (es) | Composiciones que comprenden una combinación de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo. | |
CL2017002230A1 (es) | Tratamiento combinado con un agonista de tlr7 y un inhibidor del ensamblaje de la cápsida del vhb. | |
CL2017001488A1 (es) | Benzamidas sustituidas con 1,3–tiazol–2–ilo | |
MX2020004467A (es) | Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r. | |
CO2017001493A2 (es) | Kits que comprenden inhibidores tigit y agentes anticáncer | |
CU20150096A7 (es) | Compuestos de amida y composición farmacéutica para el tratamiento de vih | |
CL2020002512A1 (es) | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak. | |
AR101312A1 (es) | Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton | |
CO2019009215A2 (es) | Sal hemi-sulfato de nucleótido para el tratamiento del virus de la hepatitis c | |
CL2020003367A1 (es) | Composición que comprende el oligonucleótido antisentido y su uso para el tratamiento de la distrofia muscular de duchenne | |
CL2016002276A1 (es) | Composiciones tópicas que comprenden un extracto de coriolus versicolor para aumentar la autoinmunidad | |
CO2020004034A2 (es) | Métodos para el tratamiento de distrofia muscular | |
UY35328A (es) | Tratamiento de formas progresivas de esclerosis múltiple con laquinimod | |
CL2019001746A1 (es) | Amidas aromáticas de ácido carboxílico | |
CO2020007601A2 (es) | Cepa vacunal de brucella modificada para el tratamiento de brucelosis | |
CL2019003463A1 (es) | Composición farmacéutica y forma de dosis farmacéutica que comprenden (e)-4-(2-(aminometil)-3-fluoroaliloxi)-n-ter-butilbenzamida, proceso para su preparación, métodos para tratamiento y usos de estas. | |
CO2017001076A2 (es) | Composiciones farmacéuticas antihiperalgésicas, antialodínicas y antiinflamatorias que contienen pregabalina y meloxicam | |
CL2022001079A1 (es) | Métodos y composiciones para el tratamiento del síndrome de rett | |
CL2021000858A1 (es) | Derivados de 4-pirazin-2-ilmetil-morfolina y su uso como medicamento | |
BR112017005241A2 (pt) | composto, e, composição farmacêutica. | |
BR112021006388A2 (pt) | composto, composição farmacêutica, uso de um composto, e, método para tratamento de uma infecção viral em um mamífero | |
PE20142020A1 (es) | Metodos para tratar el cancer usando inhibidor de pi3k e inhibidor de mek | |
CL2017001815A1 (es) | Composición fungicida efectiva contra alternaria en cítricos | |
TR201819816T4 (tr) | Tümörlerin tedavi edilmesine yönelik parvovirüs formülasyonu. |